MLTX MoonLake Immunotherapeutics - Ordinary Shares - Class A

503

$52.14

$4.91

(10.40%)

Today

Watchers	503
52-Wk Low	$9.08
52-Wk High	$63.40

Market Cap	$2.88B
Volume (M)	59,133.00
52-Wk High	$63.40
52-Wk Low	$9.08

Fundamentals

MoonLake Immunotherapeutics (NASDAQ:MLTX) Earns "Outperform" Rating from WedbushZolmax • 1 day ago

Wedbush reissued their outperform rating on shares of MoonLake Immunotherapeutics (NASDAQ:MLTX Free Report) in a research report sent to investors on Friday, Benzinga reports. The brokerage...

Share to Feed

Analysts Offer Insights on Healthcare Companies: MoonLake Immunotherapeutics (MLTX) and BioNTech SE (BNTX)TipRanks Financial Blog • 8 days ago

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on MoonLake Immunotherapeutics (MLTX Research Report...

MoonLake Immunotherapeutics (NASDAQ:MLTX) to Post FY2023 Earnings of ($0.88) Per Share, Lifesci Capital ForecastsTicker Report • 18 days ago

MoonLake Immunotherapeutics (NASDAQ:MLTX Free Report) Lifesci Capital increased their FY2023 EPS estimates for MoonLake Immunotherapeutics in a research note issued on Tuesday...

MoonLake Immunotherapeutics (NASDAQ:MLTX) Price Target Increased to $77.00 by Analysts at GuggenheimZolmax • 18 days ago

MoonLake Immunotherapeutics (NASDAQ:MLTX Get Free Report) had its price objective boosted by stock analysts at Guggenheim from $70.00 to $77.00 in a note issued to investors on Wednesday...

MoonLake Immunotherapeutics Reports Third Quarter 2023 Financial Results and Provides a Business UpdateGlobe Newswire • 22 days ago

MoonLake Immunotherapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update Announced positive full 24-week data from the global Phase 2 MIRA clinical trial, establishing...

Stifel Nicolaus Keeps Their Buy Rating on MoonLake Immunotherapeutics (MLTX)TipRanks Financial Blog • 27 days ago

Stifel Nicolaus analyst Alex Thompson CFA maintained a Buy rating on MoonLake Immunotherapeutics (MLTX Research Report) yesterday and set a price...

Positive Phase II Study Results Bolster Buy Rating for MoonLake ImmunotherapeuticsTipRanks Financial Blog • about 1 month ago

Analyst Rami Katkhuda of LifeSci Capital maintained a Buy rating on MoonLake Immunotherapeutics (MLTX Research Report), with a price target of $7...

MoonLake Immunotherapeutics announces landmark Phase 2 results for Nanobody sonelokimab in active psoriatic arthritisGlobe Newswire • about 1 month ago

MoonLake Immunotherapeutics announces landmark Phase 2 results for Nanobody sonelokimab in active psoriatic arthritis First placebo-controlled randomized trial in active psoriatic arthritis (PsA...

Cantor Fitzgerald Brokers Reduce Earnings Estimates for MoonLake Immunotherapeutics (NASDAQ:MLTX)Zolmax • about 2 months ago

MoonLake Immunotherapeutics (NASDAQ:MLTX Free Report) Research analysts at Cantor Fitzgerald cut their FY2024 earnings per share (EPS) estimates for shares of MoonLake...

MoonLake Immunotherapeutics (NASDAQ:MLTX) Stock Price Down 2.9%Ticker Report • about 2 months ago

MoonLake Immunotherapeutics (NASDAQ:MLTX Get Free Report) traded down 2.9% during mid-day trading on Tuesday . The stock traded as low as $58.76 and last traded at $58.79. 97,221 shares...